Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).
Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‐HBPOG). Mitsunaga S, et al. Among authors: ueno m. J Hepatobiliary Pancreat Sci. 2024 Sep 25. doi: 10.1002/jhbp.12071. Online ahead of print. J Hepatobiliary Pancreat Sci. 2024. PMID: 39318258
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Morizane C, et al. Among authors: ueno h, ueno m. Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26. Cancer Chemother Pharmacol. 2012. PMID: 22120961 Clinical Trial.
Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
Okusaka T, Ueno M, Sato T, Heike Y. Okusaka T, et al. Among authors: ueno m. J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):314-8. doi: 10.1007/s00534-011-0495-1. J Hepatobiliary Pancreat Sci. 2012. PMID: 22273718 Clinical Trial.
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, Sugimori K, Furuse J, Shimada K, Ioka T, Nakamori S, Baba H, Komatsu Y, Takeuchi M, Hyodo I, Boku N. Ueno M, et al. Ann Oncol. 2016 Mar;27(3):502-8. doi: 10.1093/annonc/mdv603. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681680 Free PMC article. Clinical Trial.
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S, Ishii H, Kodama Y, Morizane C, Okusaka T, Yanagimoto H, Notohara K, Taguchi H, Kitano M, Yane K, Maguchi H, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Kawaguchi Y, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Yoshida T, Hara K, Imamura M, Furuse J, Yatabe Y, Mizuno N. Hijioka S, et al. Among authors: ueno m. Clin Cancer Res. 2017 Aug 15;23(16):4625-4632. doi: 10.1158/1078-0432.CCR-16-3135. Epub 2017 Apr 28. Clin Cancer Res. 2017. PMID: 28455360
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. Ueno M, et al. Cancer Chemother Pharmacol. 2017 Aug;80(2):307-315. doi: 10.1007/s00280-017-3351-4. Epub 2017 Jun 20. Cancer Chemother Pharmacol. 2017. PMID: 28634650 Free PMC article. Clinical Trial.
2,959 results